VTCN1 and neoplasm: Our endeavor on multiomic analyses coupled with experimental validation has drawn attention to the USP10/B7‐H4 proteolytic axis as a possible pivotal target to potentiate tumor immune response and augment ADC efficacy in treating immune‐cold TNBCs.